# TRIUMEQ PD
> **NDA215413** · New Drug Application · Sponsor: VIIV HLTHCARE · Approved 2022-03-30
## Drug
- **FDA Application Number:** NDA215413
- **Application type:** New Drug Application
- **Brand name:** TRIUMEQ PD
- **Generic name:** ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE
- **Active ingredients:** ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE
- **Dosage form:** TABLET, FOR SUSPENSION
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** VIIV HLTHCARE
- **Manufacturer:** ViiV Healthcare Company
- **First approval:** 2022-03-30
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215413)
---
*MORVS · CC0 1.0*